Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 9 results found. Search for [ anti-viral Valcyte ]

Results 1 to 9 of 9
E. Kumar Sharma
Delhi, April 1, 2017
Leading Indian pharmaceutical companies are facing competition in the US from relatively smaller firms back home.

Ajay Tyagi & Munish Shekhavat
New Delhi, December 26, 2014
The government sought to put controls on drugmakers when it came to pricing of essential drugs, including those for common cough and cold as also for cancer and other diseases.

New Delhi, December 16, 2014
\"The company has launched Valganciclovir tablets, USP in the US market on December 15, 2014 and the product has been approved by USFDA\", Dr Reddy's said.

Zeba Siddiqui
Mumbai, December 4, 2014
The latest EU ban on the Dewas plant was enforced after German regulators also found quality lapses during an inspection of the site.

Zeba Siddiqui
Mumbai, December 3, 2014
After an inspection in June, Germany's drug regulator issued a 'non-compliance' report for the Madhya Pradesh plant where Ranbaxy made the antibiotic Cephalosporin.

New Delhi, November 26, 2014
Ranbaxy Laboratories had sued US Food and Drug Administration (USFDA) over revoking an approval to sell generic versions of Nexium and Valcyte in the US market.

Mumbai, November 19, 2014
Also, the drug maker is being moved out of the National Stock Exchange's CNX Nifty Junior index, which stoked selling pressure, brokers said.

E Kumar Sharma
Hyderabad, September 20, 2013
US drugs regulator says the drugmaker did not follow up with investigations into manufacturing problems.

E Kumar Sharma
September 17, 2013
Ranbaxy has been pinning its hopes on Mohali after the FDA slapped import bans on its Paonta Sahib and Dewas plants in 2008. But the extension of the Consent Decree to the Punjab plant means the drug maker is barred from supplying any products from it.